Market open
PTC Therapeutics/$PTCT
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Ticker
$PTCT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
939
ISIN
US69366J2006
Website
PTC Therapeutics Metrics
BasicAdvanced
$3.7B
6.22
$7.51
0.52
-
Price and volume
Market cap
$3.7B
Beta
0.52
52-week high
$58.38
52-week low
$28.72
Average daily volume
1.4M
Financial strength
Current ratio
3.891
Quick ratio
3.776
Long term debt to equity
-1,196.881
Total debt to equity
-1,339.405
Interest coverage (TTM)
5.11%
Management effectiveness
Return on assets (TTM)
24.42%
Return on equity (TTM)
-110.19%
Valuation
Price to earnings (TTM)
6.224
Price to revenue (TTM)
2.037
Price to book
-19.94
Price to tangible book (TTM)
-19.94
Price to free cash flow (TTM)
5.317
Growth
Revenue change (TTM)
91.12%
Earnings per share change (TTM)
-197.92%
3-year revenue growth (CAGR)
46.02%
3-year earnings per share growth (CAGR)
0.59%
What the Analysts think about PTC Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
PTC Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PTC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PTC Therapeutics News
AllArticlesVideos
Lost Money on PTC Therapeutics, Inc. (PTCT)? Possible Fraud - Contact Levi & Korsinsky Today
Accesswire·23 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Accesswire·1 day ago
Did PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCT
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $3.7B as of May 15, 2025.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 6.22 as of May 15, 2025.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of May 15, 2025.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.